Silver Investment Partners acquires specialty pharmaceuticals distributor Lucien Ortscheit

King & Wood Mallesons (KWM) has advised Silver Investment Partners (SIP) on the acquisition of a majority stake in Lucien Ortscheit GmbH (Lucien Ortscheit).

Lucien Ortscheit, based in Saarbrücken, Germany, is a leading international specialty pharmaceutical distributor focusing on unlicensed medicines and comparator drugs for clinical trials. The company is a global trader of medicines that are temporarily unavailable or unlicensed in the destination country. Lucien Ortscheit was founded in 1963 and acquired by the Kloos family in 2002. Since its foundation, the company has grown steadily and today has a broadly diversified and loyal customer base, including thousands of customers from over 60 countries. 

SIP is an independent equity finance investor for medium-sized companies in Germany, Austria and Switzerland. As an entrepreneurial, experienced and trusted partner, Silver Investment Partner engages in majority and minority interests in companies with revenues of between €5 million and €100 million, with a focus on companies with revenues of between €10 million and €50 million.

The former owners, the Kloos family, will retain a minority stake in the company. Mr. Kloos will continue to act as managing director and will be responsible for the operative business in the medium term. SIP supports Lucien Ortscheit's sustainable growth strategy. In order to further develop the company, growth opportunities such as international expansion, expansion of the product range and add-on acquisitions in a domestic and international attractive niche market shall be used. 

Advisors to Silver Investment Partners:

Dr. Michael Roos (partner), Dr. Peter Polke (counsel), Dr. Katrin Thoma (associate), Lorenz Liebsch (associate), Simon Brandt (PSL) (all Corporate/M&A)

Markus Hill (partner), Viktoria Rosbach (associate) (both Tax)